Related Pages for SUNPHARMA
- Option Chain
- Straddle OC
- Max Pain
- Put Call Ratio
- Option Analytics
- Call OI vs Put OI
- Strike Flow
- Call OI Chg vs Put OI Chg
- Call Vol vs Put Vol
- Buildup & Unwinding
- Vega Divergence
- Multi Strike OI
- Multi Straddle Analysis
- Price vs OI
- Time Series Table
- Time Series Multi Chart
- Volatility Skew
- Premium Decay
- IV - HV
- IV Intraday
- Future Chain
- Future Intraday Analysis
- Technical
- Financials
- Chart
- About
No results found.
SUNPHARMA
Related News - SUNPHARMA
SUN PHARMACEUTICAL INDUSTRIES: Q1 CONS NET PROFIT 29B RUPEES VS 23B (YOY); EST 30.5B
31 Jul 2026 02:29 PM
SUN PHARMACEUTICAL INDUSTRIES: Q1 CONS NET PROFIT 29B RUPEES VS 23B (YOY); EST 30.5B
SUN PHARMACEUTICAL INDUSTRIES: Q1 REVENUE 153B RUPEES VS 138B (YOY); EST 156.25B
31 Jul 2026 02:30 PM
SUN PHARMACEUTICAL INDUSTRIES: Q1 REVENUE 153B RUPEES VS 138B (YOY); EST 156.25B
SUN PHARMACEUTICAL INDUSTRIES: Q1 EBITDA 44.2B RUPEES VS 43B (YOY); EST 42.55B || Q1 EBITDA MARGIN 28.9% VS 31.06% (YOY); EST 27.2%
31 Jul 2026 02:30 PM
SUN PHARMACEUTICAL INDUSTRIES: Q1 EBITDA 44.2B RUPEES VS 43B (YOY); EST 42.55B || Q1 EBITDA MARGIN 28.9% VS 31.06% (YOY); EST 27.2%
SUN PHARMACEUTICAL INDUSTRIES: Q1 U.S. SALES AT USD 427M VS 473M (YOY), DOWN 10%
31 Jul 2026 02:33 PM
SUN PHARMACEUTICAL INDUSTRIES: Q1 U.S. SALES AT USD 427M VS 473M (YOY), DOWN 10%
Sun Pharmaceutical Industries: Gets Approval From Anvisa To Produce And Sell Semaglutide In Brazil
29 Jul 2026 10:06 PM
Sun Pharmaceutical Industries: Gets Approval From Anvisa To Produce And Sell Semaglutide In Brazil
Sun Pharmaceutical Industries: Partner Philogen Re-Submits NIDLEGY™ Application To EMA For Advanced Melanoma Treatment.
27 Jul 2026 04:03 PM
Sun Pharmaceutical Industries: Partner Philogen Re-Submits NIDLEGY™ Application To EMA For Advanced Melanoma Treatment.
Sun Pharma: Gets Green Light To Produce And Sell Generic Semaglutide In South Africa; Launching Soon As Ready-To-Use Multi-Dose Injectable Pen.
15 Jul 2026 08:56 AM
Sun Pharma: Gets Green Light To Produce And Sell Generic Semaglutide In South Africa; Launching Soon As Ready-To-Use Multi-Dose Injectable Pen.
Sun Pharmaceutical Industries: Will Hold Q1 Earnings Call On July 31 At 6:30 PM.
14 Jul 2026 08:31 PM
Sun Pharmaceutical Industries: Will Hold Q1 Earnings Call On July 31 At 6:30 PM.
Sun Pharmaceutical Industries: Plans To Review Q1 Results On July 31.
10 Jul 2026 03:55 PM
Sun Pharmaceutical Industries: Plans To Review Q1 Results On July 31.
Sun Pharma: Co To Buy 100% Of Innovcare Lifesciences || Deal Value 2.71b Rupees
20 Jun 2026 05:32 PM
Sun Pharma: Co To Buy 100% Of Innovcare Lifesciences || Deal Value 2.71b Rupees
Sun Pharmaceutical Industries: Citi maintains a Buy on Sun Pharmaceutical Industries with a Target Price of ₹2180, citing strong ASCO 2026 data reinforcing UNLOXCYT’s competitive positioning in laCSCC, improved confidence on efficacy and tolerability, and supporting expectations of $400m+ peak sales by FY30.
27 May 2026 08:56 AM
Sun Pharmaceutical Industries: Citi maintains a Buy on Sun Pharmaceutical Industries with a Target Price of ₹2180, citing strong ASCO 2026 data reinforcing UNLOXCYT’s competitive positioning in laCSCC, improved confidence on efficacy and tolerability, and supporting expectations of $400m+ peak sales by FY30.
Sun Pharma: Company Will Not Provide Margin Guidance, Expects West Asia War to Affect Future Quarters, and Noticing Increase in Logistics and Shipping Costs.
25 May 2026 12:57 PM
Sun Pharma: Company Will Not Provide Margin Guidance, Expects West Asia War to Affect Future Quarters, and Noticing Increase in Logistics and Shipping Costs.
Sun Pharma: Expects Top-Line Growth In High Single Digits For FY27, Considering Current Regulatory And Economic Conditions. R&D Expenses Are Estimated To Be 6% To 7% Of Sales, With An Expected Effective Tax Rate Of 25% For Next Year And Beyond.
25 May 2026 09:13 AM
Sun Pharma: Expects Top-Line Growth In High Single Digits For FY27, Considering Current Regulatory And Economic Conditions. R&D Expenses Are Estimated To Be 6% To 7% Of Sales, With An Expected Effective Tax Rate Of 25% For Next Year And Beyond.
Sun Pharma: Reports U.S. Formulation Sales At $459 Million, Down 1.1%.
22 May 2026 02:48 PM
Sun Pharma: Reports U.S. Formulation Sales At $459 Million, Down 1.1%.
SUN PHARMACEUTICAL INDUSTRIES: Q4 CONS NET PROFIT 27B RUPEES VS 21.5B (YOY); EST 28B
22 May 2026 02:45 PM
SUN PHARMACEUTICAL INDUSTRIES: Q4 CONS NET PROFIT 27B RUPEES VS 21.5B (YOY); EST 28B
SUN PHARMACEUTICAL INDUSTRIES: Q4 EBITDA 39.54B RUPEES VS 37.16B (YOY) || Q4 EBITDA MARGIN 27.1% VS 28.68% (YOY) - AS PER STATEMENT
22 May 2026 02:45 PM
SUN PHARMACEUTICAL INDUSTRIES: Q4 EBITDA 39.54B RUPEES VS 37.16B (YOY) || Q4 EBITDA MARGIN 27.1% VS 28.68% (YOY) - AS PER STATEMENT
SUN PHARMACEUTICAL INDUSTRIES: Q4 REVENUE 146B RUPEES VS 129.59B (YOY)
22 May 2026 02:46 PM
SUN PHARMACEUTICAL INDUSTRIES: Q4 REVENUE 146B RUPEES VS 129.59B (YOY)
Sun Pharma: May Face Increased Scrutiny Due To CDSCO's Action Against Cosmetic Injectables.
21 May 2026 10:46 AM
Sun Pharma: May Face Increased Scrutiny Due To CDSCO's Action Against Cosmetic Injectables.
